Esin AVŞAR, Mustafa AYDEMİR, Hasan SÖZEL, Mustafa Serkan ALEMDAR

DİYABETİK SÜREÇTE MONOSİT/HDL-KOLESTEROL VE NÖTROFİL/HDL-KOLESTEROL ORANLARI

Giriş: Monosit/HDL-kolesterol oranı (MHO) ve nötrofil/HDL-kolesterol oranı(NHO) kronik hastalıklar için subklinik inflamasyonun basit ve ucuz belirteçleridir. Bu çalışma, farklı glukoz toleranslarına sahip katılımcılarda MHO ve NHO'yu değerlendirmeyi amaçladı. Gereç ve Yöntem: 1112 hasta (erkek / kadın = 392/720) OGTT sonuçlarına göre beş gruba ayrıldı: grup 1 = normal glikoz toleransı (NGT), grup 2 = bozulmuş açlık glikozu (BAG), grup 3 = izole bozulmuş glukoz toleransı (BGT), grup 4 = hem BAG hem de BGT ve grup 5 = tip 2 diabetes mellitus (T2DM). Sonuçlar gruplar arasında karşılaştırıldı. Bulgular: Çalışmaya dahil edilen katılımcıların yaş ortalaması 50,03±13,62 olarak bulundu. %35,2’si erkek %64,7’si kadındı. Hastaların NGT grubundan T2DM grubuna ilerledikçe HbA1c, kreatinin, trigliserit, glukoz ve NHO değerlerinin arttığı, tahmini glomerüler filtrasyon hızı (tGFH) ve yüksek dansiteli lipoprotein kolesterol (HDLK) değerlerinin ise azaldığı görüldü (p

MONOCYTE / HDL-CHOLESTEROL AND NEUTROPHIL / HDL-CHOLESTEROL RATIOS IN THE DIABETIC PROCESS

inexpensive markers of subclinical inflammation for chronic diseases. This study aimed to evaluate MHR and NHR in participants with different glucose tolerances. Material and Method: 1112 participants (male/female=392/720) were divided into five groups according to OGTT results: group 1 = normal glucose tolerance (NGT), group 2 = impaired fasting glucose (IFG), group 3 = isolated impaired glucose tolerance (IGT), group 4 = both IFG and IGT, and group 5 = type 2 diabetes mellitus (T2DM). Results were compared between groups. Results: The mean age of participants included in the study was 50.03 ± 13.62 years. 35.2% were men and 64.7% were women. HbA1c, creatinine, triglyceride, glucose and NHR values increased, while estimated glomerular filtration rate (eGFR) and high density lipoprotein cholesterol (HDL-C) values decreased as the patients progressed from the NGT group to the T2DM group(p

PDF

___

1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53
2. Ninomiya T, Perkovic V, De Galan BE, Zoungas S, Pillai A, Jardine M et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20(8): 1813-21.
3. Fox CS, Coady S, Sorlie PD, D’Agostino RB, Pencina MJ, Vasan RS et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 2007; 115(12): 1544-50.
4. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 2002; 19(9): 708-23.
5. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016; 241(12): 1323-31.
6. Müller-Wieland PD med D, Nauck M, Petersmann A, Müller-Wieland D, Schleicher E, Müller UA et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Diabetologe 2019; 15(2): 128–34.
7. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010; 31(2): 171-82.
8. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11(11): 762-74.
9. Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: Circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2014; 2(1): 1.
10. Mestas J, Ley K. Monocyte-Endothelial Cell Interactions in the Development of Atherosclerosis. Trends Cardiovasc Med 2008; 18(6): 228-32.
11. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17(2): 368- 77.
12. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004; 109(23)1: 308-14.
13. Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014; 46(8): 1619-25.
14. You S, Zhong C, Zheng D, Xu J, Zhang X, Liu H et al. Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J Neurol Sci 2017; 372: 157-61
15. Karataş MB, Çanga Y, Özcan KS, Ipek G, Güngör B, Onuk T et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med 2016; 34(2): 240-4.
16. Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Çay S et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015; 17(12): 1807-15.
17. Canpolat U, Çetin EH, Cetin S, Aydin S, Akboga MK, Yayla C et al. Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clin Appl Thromb Hemost 2016; 22(5): 476-82.
18. Balta S, Celik T, Ozturk C, Kaya MG, Aparci M, Yildirim AO et al. The relation between monocyte to HDL ratio and noreflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med 2016; 34(8): 1542-7.
19. Chen T, Chen H, Xiao H, Tang H, Xiang Z, Wang X et al. Comparison of the value of neutrophil to high-density lipoprotein cholesterol ratio and lymphocyte to high-density lipoprotein cholesterol ratio for predicting metabolic syndrome among a population in the southern coast of China. Diabetes Metab Syndr Obes 2020; 13: 597-605.
20. Ancuta P, Wang J, Gabuzda D. CD16 + monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells . J Leukoc Biol 2006; 80(5): 1156-64.
21. Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32(3): 213-29.
22. Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC. Protective effect of high density lipoprotein on endotheliumdependent vasodilatation. Int J Cardiol 2000; 73(3): 231-6.
23. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044(2): 275–83.
24. Chen JW, Li C, Liu ZH, Shen Y, Ding FH, Shu XY et al. The role of monocyte to high-density lipoprotein cholesterol ratio in prediction of carotid intima-media thickness in patients with type 2 diabetes. Front Endocrinol (Lausanne) 2019; 10(4): 1– 11.
25. Karatas A, Turkmen E, Erdem E, Dugeroglu H, Kaya Y. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomark Med 2018; 12(9): 953–9.
26. Onalan E. The relationship between monocyte to high-density lipoprotein cholesterol ratio and diabetic nephropathy. Pakistan J Med Sci 2019; 35(4): 1081–6.
27. Jialal I, Jialal G, Adams-Huet B, Ramakrishnan N. Neutrophil and monocyte ratios to high-density lipoprotein-cholesterol and adiponectin as biomarkers of nascent metabolic syndrome. Horm Mol Biol Clin Investig 2020; 41(2): 1–9.
28. Huang JB, Chen YS, Ji HY, Xie WM, Jiang J, Ran L Sen et al. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: A comparison study. Lipids Health Dis 2020; 19(1): 59.